In their pilot study, Balta et al reported that circulating endocan (endothelial cell specific molecule 1 [ESM-1]) levels may represent a new marker of essential hypertension. 1 They found that in 18 patients with newly diagnosed hypertension, serum endocan levels correlated significantly with carotid intimamedia thickness (cIMT) and high-sensitivity C-reactive protein (hsCRP) compared with 23 normotensive controls. 1 Therefore, Balta et al suggested that circulating endocan levels may represent a new marker for essential hypertension. 1 Endocan is a protein encoded by the ESM-1 gene in humans. 2 Due to possible confusion, it must be clarified that endocan is not related to endocannabinoids that are endogenous mediators that elicit multiple biological effects similar to those of marijuana. 3 The focus of this editorial is specifically on endocan and its CV relationships.
Endocan is a recombinant proteoglycan that can be produced from engineered HEK293 cells with efficient longterm production. This availability opens new opportunities to study the structure and functions of endocan. 4 Abid et al tested the hypothesis that endocan, as a novel soluble dermatan sulfate proteoglycan, is differentially expressed in the intact endothelium and that site-specific expression is mediated by signals in the local microenvironment. 5 Using a combination of analytical techniques, they reported that endocan is preferentially expressed in the endothelial lining of tumor xenografts, including human nonsmall cell lung cancer, rat glioma, and human renal cell carcinoma. They found that in vitro expression of endocan in human umbilical vein endothelial cells (HUVECs) was upregulated by a tumor cell-conditioned medium and that this was inhibited by the addition of neutralizing antibody to vascular endothelial growth factor (VEGF). The authors also found that treatment of HUVEC with VEGF resulted in a dose-and time-dependent increase in messenger RNA (mRNA) in endocan. 5 It therefore appeared to them that endocan is preferentially expressed in tumor endothelium in vivo with its expression regulated by tumor-derived factors. Akkök et al reported that peripheral blood stem cell (PBSC) collection in patients with multiple myeloma using PBSC apheresis decreased the angioregulatory cytokines, angiopoietin 22 and VEGF, which had been found to be increased in the patients with myeloma, while at the same time, PBSC apheresis resulted in an increase in endocan levels as a microvascular endothelial marker. 6 Rennel et al appeared to show that among angiogenic growth factors, VEGF-A is a specific inducer of endocan transcription. 7 This translates into increased protein levels in VEGF-A-treated endothelial cells. Rennel et al suggested that increased endocan protein expression in human renal cancer supports its role in tumor growth. Similar supportive data are available for colorectal cancer. When colorectal cancer is present, the expression of endocan is downregulated. 8 However, endocan is positively correlated with tissue differentiation in colorectal cancer, which suggests that endocan is associated with the development and differentiation of colorectal cancer. 8 Zhang et al studied endocan as a novel human endothelial cell-specific molecule whose expression is regulated by cytokines and VEGF. 9 They found that endocan was expressed in actively proliferative or neogenic tissues and cells such as the germinal centers of lymph nodes, bronchial epithelium, neovasculature, endothelium, and glandular tissues. Endocan was not present in silent or resting tissues of cells such as the endothelium of the spleen and large arteries. Zhang et al considered that endocan may function as a marker for angiogenesis or oncogenesis and that the gene for endocan might be a candidate gene for the development of inflammatory tissue, metastases, neoplasia, and the development of tumors such that the expression level of endocan may be of value in early diagnosis and prognosis of some tumors. 9 In line with this, Roudnicky et al found that both endocan and VEGF-A levels were more elevated in the plasma of patients with invasive bladder cancer than in healthy individuals. 10 They therefore postulated that endocan might function as a useful biomarker for monitoring disease progression and the efficacy of therapies to target VEGF-A in patients with bladder cancer. Endocan has also been found to be overexpressed in renal clear cell carcinomas and as a result it may be a target marker for follow-up of these cancers and a potential way to evaluate their response to antiangiogenic therapies. 11 Serum endocan has also been shown to be a disease marker in acute myeloid leukemia but subject to the effects of complicating infections and the regeneration of bone marrow. 12 Similar results have been reported for nonsmall cell lung cancer compared to healthy lung with endocan overexpressed in this lung cancer and possibly reflecting tumor angiogenic stimulation with also prognostic significance. 13 Similar results pertain to hepatocellular carcinoma in which tumor-associated endothelial cells show an overexpression of endocan with a close relationship to the angiogenesis and the pathogenesis of the tumor also suggesting endocan as a useful marker of tumor progression. 14 Because of the data showing that endothelial-derived endocan induces tumor growth and that endocan blood levels may be an innovative marker for cancer, the possibility of antibodies to endocan has been considered a cancer therapeutic target. 15 Based on recent immunotherapeutic approaches in cancer, preclinical data involving endocan have suggested antibody against its protein core as a possible promising cancer therapy. 16 Endocan expression is associated with tumorigenic properties and is the product of a single gene composed of 3 exons. Depontieu et al identified and functionally characterized the alternative spliced product of the endocan gene, specifically, exon 2-deleted endocan, also called endocanDelta2. 17 These authors found that the exon 2 deletion impairs synthesis of the glycan chain, which is known to be involved in the tumor-promoting effect of endocan. Various cell lines of human and murine origin were implanted in the skin of severe combined immunodeficient mice, and endocanDelta2 did not promote tumor formation, suggesting that effecting the exon 2 deletion could be a future cancer therapy target. 17 The overwhelming clinical evidence associated with endocan involves cancer but what about a CV relationship? Balta et al studied a total of 29 patients with psoriasis vulgaris and 35 controls. 18 The authors measured the following in all patients: endocan, hsCRP, and cIMT. The serum endocan levels were significantly different between the 2 groups. In the patients with psoriasis, serum endocan levels correlated significantly with the psoriasis activity and severity index, hsCRP, and cIMT. 18 The article presents evidence that may represent a new marker that correlates with CV risk as well as severity of disease in psoriasis vulgaris. Balta et al also studied the relationship between serum levels of endocan and disease activity in patients with Behçet disease, which is an inflammatory disease involving multiple sites, in a small study of 33 patients and 35 healthy individuals. 19 In patients with Behçet disease, the authors found that serum endocan levels were significantly increased compared to the healthy individuals and in addition, the increased endocan levels correlated moderately, but significantly, with increased CRP, increased erythrocyte sedimentation rate, and Behçet disease activity. 19 Endocan may be a surrogate endothelial dysfunction marker with also a role in endothelium-dependent pathological disorders, 18, 19 extending to CV disease in addition to the extensive literature involving cancers. This status of endocan as a surrogate marker for endothelial dysfunction was also suggested by Balta et al in their article describing circulating endocan levels as a new marker for patients with essential hypertension. 1 It appears that endocan as a recombinant proteoglycan more associated with cancer may have significance as a clinical marker for hypertension and other CV disease.
